Business Description
Compare
Compare
Traded in other countries / regions
0VY.GermanyIMAB.USA Description
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 37.77 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 0.52 | |||||
| Beneish M-Score | 2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.3 | |||||
| 3-Year EBITDA Growth Rate | -56.1 | |||||
| 3-Year EPS without NRI Growth Rate | -32.8 | |||||
| 3-Year FCF Growth Rate | -29.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.07 | |||||
| 9-Day RSI | 64.05 | |||||
| 14-Day RSI | 64.67 | |||||
| 6-1 Month Momentum % | -69.53 | |||||
| 12-1 Month Momentum % | -84.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.31 | |||||
| Quick Ratio | 7.31 | |||||
| Cash Ratio | 6.65 | |||||
| Days Inventory | 137.42 | |||||
| Days Sales Outstanding | 51.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.5 | |||||
| Operating Margin % | -1511.82 | |||||
| Net Margin % | -1882.31 | |||||
| ROE % | -48.96 | |||||
| ROA % | -41.06 | |||||
| ROIC % | -218.68 | |||||
| ROC (Joel Greenblatt) % | -1653.2 | |||||
| ROCE % | -42.42 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.06 | |||||
| PB Ratio | 0.94 | |||||
| Price-to-Tangible-Book | 1.01 | |||||
| EV-to-EBIT | -0.01 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | -0.01 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-Revenue | 0.12 | |||||
| EV-to-Forward-Revenue | 0.23 | |||||
| EV-to-FCF | -0.01 | |||||
| Price-to-Net-Current-Asset-Value | 1.13 | |||||
| Price-to-Net-Cash | 1.28 | |||||
| Earnings Yield (Greenblatt) % | -10000 |
